$OPTU

Top insider buys and sells from Friday’s market activity

On August 28, 2026, notable insider trading included Optimum Communications (OPTU) director Neil S. Subin buying $2.45M in shares, REGENXBIO (RGNX) director Gregory Austin Ciongoli purchasing $949K, and Pulse Biosciences (PLSE) COO Liane Rae Teplitsky acquiring $99K. United States Antimony (UAMY) CEO Gary C. Evans bought $98K in shares, while Battalion Oil (BATL) director William D. Rogers purchased $91K. On the sell side, Life Time Group (LTH) insiders sold $126M, Relay Therapeutics (RLAY) 10%

Original reporting
Published Aug 31, 2026, 1:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 31, 2026, 1:06 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$OPTU
Bullish
medium confidence
Mentioned
$OPTU · $RGNX · $PLSE · $UAMY · $BATL · $LTH
Relevance
4/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$OPTUBullishLow
01

Why it matters

Provides traders with direct insight into insider sentiment, which can be a leading indicator for short‑term price moves.

02

Market read

Insider activity across these tickers may influence short‑term trading decisions, especially for the larger transactions in LTH, RLAY, and SNOW.

03

What to watch

Potential hidden strategic moves or upcoming financing not disclosed.

Relevance 4/10Novelty 3/10Timing: insider filings disclosed August 28, 2026

Background

The article aggregates recent Form 4 insider transactions across several U.S. listed companies.

Company-level read

Ticker impact

$OPTUBullishMedium confidence
Context

Director Neil S. Subin bought $2.45M of OPTU shares, indicating insider confidence despite a 20% weekly surge.

Expected impact

Modest upside if buying pressure continues.

Evidence & confidence

Insider purchase size relative to float suggests belief in near-term performance.

$RGNXBullishLow confidence
Context

Director Gregory Austin Ciongoli purchased $949k of RGNX stock, showing belief in the biotech despite a 13% weekly decline.

Expected impact

Limited upside unless broader biotech sentiment improves.

Evidence & confidence

Purchase size modest; market already discounting.

$PLSENeutralLow confidence
Context

COO Liane Rae Teplitsky bought $99,965 of PLSE shares near its 52‑week high, indicating insider support.

Expected impact

Potential stabilization rather than strong rally.

Evidence & confidence

Purchase small relative to market cap; stock already near peak.

$UAMYBullishLow confidence
Context

CEO Gary C. Evans bought 20,000 UAMY shares for $98,400, a modest stake increase amid a 46% six‑month decline.

Expected impact

Possible modest upside if market perceives buy‑back support.

Evidence & confidence

Purchase size small; broader commodity exposure dominates.

$BATLBullishLow confidence
Context

Director William D. Rogers acquired 70,000 BATL shares for $91,168 while the stock sits near its 52‑week low.

Expected impact

Limited upside unless oil sector improves.

Evidence & confidence

Purchase modest; sector fundamentals weak.

$LTHBearishMedium confidence
Context

Directors sold roughly $126M of LTH shares at $43.8 each, reflecting significant insider divestment after a 56% annual rally.

Expected impact

Potential short‑term downside.

Evidence & confidence

Sell size large relative to float; could signal concerns.

$RLAYBearishMedium confidence
Context

SVF Pauling (Cayman) Ltd sold 6M RLAY shares for $116.4M after a 426% price surge, indicating profit taking.

Expected impact

Short‑term price pressure expected.

Evidence & confidence

Large block sale after massive rally suggests valuation concerns.

$SNOWNeutralLow confidence
Context

Director Benoit Dageville sold 50,000 SNOW shares for $15.47M under a 10b5‑1 plan, reflecting routine liquidity.

Expected impact

Minimal price effect.

Evidence & confidence

Pre‑arranged plan; market likely priced in.

Market effects

Broad insider activity highlights heightened scrutiny in biotech and energy sectors.

U.S. market participants may adjust exposure to small‑cap biotech and oil stocks.

Limited; primarily affects U.S. listed micro‑cap equities.

Counterpoint

Insider sells may be routine liquidity events, not bearish signals.

Key entities

  • Neil S. Subin

    OPTU insider buyer

  • Gregory Austin Ciongoli

    RGNX insider buyer

  • Liane Rae Teplitsky

    PLSE insider buyer

  • Gary C. Evans

    UAMY insider buyer

  • William D. Rogers

    BATL insider buyer

Related articles

$UAMYHigh

United States Antimony Soars 11% While Rare Earth Peers Retreat; USA Rare Earth Drops 3%, Critical Metals Falls 4%

United States Antimony (UAMY) rose 11% to $3.18, while USA Rare Earth (USAR) fell 3% and Critical Metals (CRML) dropped 4%. UAMY benefits from a $245M Defense Logistics Agency contract, with Q3 2026 deliveries increasing. The company cut revenue guidance to $60M-$75M but expects antimony prices to stay around $10/lb. USAR and CRML focus on rare earth elements, with USAR expanding its supply chain and CRML awaiting project approvals.

$RGNXMedAI 9/10

RGX-202 Meets Primary End Point in Phase 3 Duchenne Trial

REGENXBIO's RGX-202 met the primary end point in a phase 3 trial for Duchenne muscular dystrophy, achieving mean microdystrophin expression exceeding 10% of normal levels at week 12. The study, presented at the 2026 Child Neurology Society Annual Meeting, showed functional improvements in participants. RGX-202 was well tolerated, with common adverse events including vomiting, fatigue, and nausea. The company reported two serious but resolved adverse events.

$SNOWMed

Snowflake (SNOW) Needham Stock Forecast & Analysis

Needham & Company reaffirmed its Buy rating and $450 price target for Snowflake (SNOW). The company reported a 37% year-over-year increase in product revenue to $1.49 billion and a 27% rise in customers spending over $1 million annually. Snowflake also raised its full-year product revenue forecast to $6.07 billion. The stock's performance hinges on customer expansion and AI product adoption.